A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects

NCT ID: NCT06057103

Last Updated: 2024-11-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-28
• Study Completion Date: 2024-04-26

Brief Summary

The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in healthy Chinese adult subjects.

The seongdary object is evaluating combined or uncombined multiple oral oseltamivir phosphate in healthy Chinese adult subjects.

Conditions

Drug Interaction

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ZX-7101A-1

Group Type: OTHER

ZX-7101A

Intervention Type: DRUG

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Oseltamivir

Intervention Type: DRUG

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

ZX-7101A and Oseltamivir

Intervention Type: DRUG

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

ZX-7101A-2

Group Type: OTHER

ZX-7101A

Intervention Type: DRUG

ZX-7101A Tablets single dose tablet, 80 mg, Oral

ZX-7101A and Oseltamivir

Intervention Type: DRUG

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Oseltamivir

Intervention Type: DRUG

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Oseltamivir-1

Group Type: OTHER

Oseltamivir

Intervention Type: DRUG

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

ZX-7101A

Intervention Type: DRUG

ZX-7101A Tablets single dose tablet, 80 mg, Oral

ZX-7101A and Oseltamivir

Intervention Type: DRUG

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Oseltamivir-2

Group Type: OTHER

Oseltamivir

Intervention Type: DRUG

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

ZX-7101A and Oseltamivir

Intervention Type: DRUG

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

ZX-7101A

Intervention Type: DRUG

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Combined-1

Group Type: OTHER

ZX-7101A and Oseltamivir

Intervention Type: DRUG

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

ZX-7101A

Intervention Type: DRUG

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Oseltamivir

Intervention Type: DRUG

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Combined-2

Group Type: OTHER

ZX-7101A and Oseltamivir

Intervention Type: DRUG

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Oseltamivir

Intervention Type: DRUG

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

ZX-7101A

Intervention Type: DRUG

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Interventions

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention Type: DRUG

Oseltamivir

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention Type: DRUG

ZX-7101A and Oseltamivir

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention Type: DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention Type: DRUG

Oseltamivir

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

Intervention Type: DRUG

ZX-7101A and Oseltamivir

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

Intervention Type: DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Healthy male or female subjects between the ages of 18 and 45 years (including the threshold value, based on the date of signing ICF).

Weight: Male weight ≥50 kg, female weight ≥45 kg, BMI between 19.0 and 28.0 kg/m2 (including cut-off value), BMI= weight (kg)/height 2 (m2).

The investigator judged the subjects to be in good overall health based on their medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (routine blood work, urine work, blood biochemistry, coagulation function), viral serology, and chest X-ray results (normal or abnormal test results have no clinical significance).

Fertile female subjects or male subjects who voluntarily signed ICF should be no fertile, sperm/egg donation for 6 months (female) or 90 days (male) from the beginning to the last dose, and voluntary use highly effective contraception (including partner) (non-drug contraception is required during the trial).

Fully understand the trial content and possible adverse reactions, have the ability to communicate with researchers normally, while complying with study requirements, follow protocol procedures and restrictions, and be able to visit on time.

Exclusion Criteria

Subjects with a prior or present history of clinically abnormal metabolic, liver, kidney, hematological, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disease who were judged by the investigator to be unsuitable for participation in this study.

Subjects with digestive tract disease or any condition that may affect drug absorption, such as a history of liver and gallbladder disease, gastrointestinal disease, gastrointestinal surgery (except appendectomy) or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.

Allergic constitutions (such as allergies to two or more drugs, foods, and pollen), or determined by the investigator, may be allergic to the investigational product or any component of the investigational product.

Acute respiratory infections within 2 weeks before screening; Or have a history of fungal infection.

For patients with abnormal vital signs (blood pressure, pulse rate, ear temperature) and clinically significant results, the abnormal values of each vital sign are:Body temperature (ear temperature) >37.5 ℃; Systolic blood pressure (recumbent) <90 mmHg or ≥140 mmHg; Diastolic blood pressure (lying) <50 mmHg or ≥90 mmHg; Pulse rate (lying position) <50 beats/min or >100 beats/min.

QTcF interval > 450ms or < 300 ms (Fridericia's correction), or QRS>120ms. Abnormal liver function: alanyl aminotransferase (ALT) or aspartate aminotransferase (AST) higher than the upper limit of normal or serum total bilirubin (TBIL) greater than 1.5 times the upper limit of normal, who judged clinical significance by investigators.

Subjects estimate glomerular filtration rate <90 mL/min/1.73 m2. Subjects virus serological test (hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, treponema pallidum specific antibody TPPA) positive results.

Subjects with a history of drug abuse (morphine, dimethylene dioxyamphetamine, methamphetamine, THC, ketamine, cocaine) or who screened positive for drug abuse.

Women who are pregnant or breastfeeding, or who test positive for blood pregnancy.

Subjects who have used any P-gp or CYP inducer or inhibitor within 30 days before screening, or any prescription or Chinese herbal medicine within 4 weeks before the start of the trial, or over-the-counter or health care products (including polyvalent cations and metal supplements, etc.) within 2 weeks before the start of the trial; It should have a longer time interval if the elimination half-life is longer-at least 5 elimination half-lives for the drug.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Nanjing Zenshine Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

ZX-7101A-208

Identifier Type: -

Identifier Source: org_study_id